A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for UK and US health systems. These findings support changing current policy to expand genetic testing to all women with BC.

https://jamanetwork.com/journals/jamaoncology/article-abstract/2752373